Sponsors (66)
The bill aims to speed development and access to ALS and other rare‑disease therapies by increasing regulatory support, planning, and oversight, but it raises federal costs and creates trade‑offs around patient safety, privacy, and funding certainty for some stakeholders.
People with ALS and other rare diseases (patients) are likely to see faster and clearer access to new therapies because the bill strengthens regulatory support, requires a 5‑year FDA action plan, and mandates updated GAO analysis to guide policy.
Researchers, developers, and health systems get clearer expectations, increased grant/contract authority, and greater transparency on FDA priorities, helping planning, investment, and speeding development of rare‑disease treatments.
Congress, agencies, patient communities, and families gain improved oversight, coordination, and evidence (through a required GAO report and mandated FDA engagement with non‑ALS rare disease communities), which should support better policy decisions and stakeholder alignment.
Accelerating development and approval pathways could increase risks to patient safety if post‑market surveillance and other safeguards are not strengthened or fully resourced.
Direct appropriations and other program costs increase federal spending and could add to the deficit or crowd out other priorities if not offset.
Changes to grant eligibility rules or replacement text could narrow or shift who receives support, creating uncertainty and possibly leaving some patients or developers with reduced access to grants.
Based on analysis of 5 sections of legislative text.
Amends and reauthorizes ALS-related programs to broaden grant review authority, expand qualifying clinical-trial definitions, require an FDA 5-year action plan update, and mandate a GAO report.
Amends and reauthorizes an existing ALS-focused law to broaden how grants and clinical trials are treated, require an updated FDA five-year action plan for ALS and other rare neurodegenerative diseases, and require a GAO evaluation of program outcomes. It expands the kinds of clinical trials counted for grant purposes and gives the Secretary authority to review trial enrollment status and request interim trial data when renewing certain grants. The bill also directs the FDA to publish, within one year, an updated 5-year action plan and assessment of the agency’s 2022 Rare Neurodegenerative Diseases Action Plan, and it requires the Government Accountability Office to deliver a multi-year report on program results within four years. Some amendatory text is not included in the excerpt, so precise changes to the original statute and funding details are not fully specified here.
Introduced April 6, 2026 by Mike Quigley · Last progress April 6, 2026